Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity

Lausanne, Switzerland, December 16, 2019 Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinsons disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.